Vyloy, Astellas and FDA Approval
Astellas nabs class-first FDA approval for CLDN18.2 gastric cancer med Vyloy
After a prior rejection, Astellas can head into the weekend celebrating a class-first FDA approval for its new gastric cancer med Vyloy. | Astellas' Vyloy won an FDA approval to treat gastric or gastroesophageal junction adenocarcinoma patients whose tumors are CLDN18.
Astellas Pharma's Cancer Drug Vyloy Gets FDA Approval
Astellas Pharma's drug Vyloy was approved for treatment of advanced gastric and gastroesophageal junction cancer by the Food and Drug Administration.
Astellas Pharma's VYLOY Receives FDA Approval For Treatment Of Advanced Gastric And GEJ Cancer
Astellas Pharma Inc. (ALPMY, ALPMY) said that the U.S. Food and Drug Administration has approved VYLOY (zolbetuximab-clzb) in
Astellas Pharma Inc.: Astellas' VYLOY (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer
VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive TOKYO, Oct. 18
FDA approves Astellas' gastric cancer therapy
The U.S. Food and Drug Administration approved Astellas' therapy to treat a type of gastric cancer, the health regulator's website showed on Friday. The therapy, branded as Vyloy, was approved to be used in combination with a type of chemotherapy for patients with a type of cancer which begins in the gastroesophageal junction,
FierceBiotech9d
UPDATED: Astellas unveils new Japan site for cell therapy research arm Universal Cells, transferring 12 roles overseas
Some six years after picking up Seattle’s Universal Cells for $102 million, Astellas Pharma is opening a second location for ...
News Medical on MSN1d
New combination treatment authorized for unresectable urothelial cancer patients
Astellas Pharma Ltd. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for PADCEV™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) in ...
PMLiVE9d
Astellas and AviadoBio enter exclusive dementia gene therapy deal worth over $2bn
Astellas Pharma and AviadoBio have entered into an exclusive option and licence agreement worth over $2bn for an ...
FierceBiotech11d
Astellas pays $50M for option on AviadoBio's dementia gene therapy
Astellas has turned to AviadoBio to further boost its gene therapy pipeline, paying the British biotech $50 million in equity ...
Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Up 269.5% in September
Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) was the target of a large growth in short interest during the month of ...
The Pharma Letter10d
Astellas inks gene therapy deal with AviadoBio
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license ...
FiercePharma8d
Fierce Pharma Asia—AstraZeneca-CSPC heart med deal; Astellas' gene therapy pact, new cell therapy site
AstraZeneca has bagged a cardiovascular disease candidate from China's CSPC Pharma in a deal potentially worth $2 billion.